Scilex Holding Company (SCLXW)

Market Cap	24.58M
Revenue (ttm)	50.71M
Net Income (ttm)	-74.51M
Shares Out	6.95M
EPS (ttm)	-14.13
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	963
Open	0.1043
Previous Close	0.1000
Day's Range	0.0998 - 0.1097
52-Week Range	0.0375 - 0.5300
Beta	1.11
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 7, 2025

About SCLXW

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of ...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• CEO: Jaisim Shah
• Employees: 115
• Stock Exchange: NASDAQ
• Ticker Symbol: SCLXW
• Website: https://www.scilexholding.com

Financial Performance

In 2024, Scilex Holding Company's revenue was $56.59 million, an increase of 21.07% compared to the previous year's $46.74 million. Losses were -$72.81 million, -56.40% less than in 2023.